BIA (BioIndustry Association) welcomes move to revamp UK pre-emption policy:
This article was originally published in Clinica
The UK's BioIndustry Association (BIA) has welcomed a report reviewing current pre-emption guidelines and whether they inhibit public companies from raising adequate funding from the capital markets. The BIA highlighted the report's criticism of the "blanket approach to disapplying pre-emption rights...due to a rigid interpretation of the guidelines". The BIA welcomes the recommendations of report author Paul Myners that the guidelines should be replaced to allow for a "case-by-case engagement between a company's directors and shareholders" and that there be a more proactive monitoring of their application, under a new pre-emption group. The current fund-raising thresholds stand at 5% of issued share capital per year, and up to 7.5% over a three-year period. The BIA wants the 5% limit raised to 20%.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.